Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT03090282 Completed - Clinical trials for Aggressive Periodontitis, Generalized

Subgingival Microbiota Following Mechanical Treatment and it's Effect on Peri-implant Sub-mucosa in Periodontitis Patients

Start date: April 1, 2016
Phase:
Study type: Observational

The investigators planed to observe the microbiome of an aggressive periodontitis patient, during mechanical treatment, surgery(if indicated) and implant placement. The investigators designed to observe the changes after mechanical treatment.Then, the investigators will compare the sub-mucosa microbiome of implant and the subgingival community. The investigators expected a different community after treatment, and there could be similarity between implant and nature teeth.

NCT ID: NCT03089970 Completed - Clinical trials for Upper Respiratory Tract Infections, Asthma, Exhaled Breath

Using Breath Metabolites to Determine Specific Virus Infection in Asthmatic Patients

Start date: February 1, 2017
Phase:
Study type: Observational

Respiratory virus infections cause a majority of asthma exacerbations in the fall to spring months. Current diagnostic platforms for respiratory viruses have limitations including cost, availability, and invasiveness. The use of noninvasive breath collection to analyze breath metabolites may be used to differentiate virus-infected asthmatics from other causes of acute asthma exacerbations.

NCT ID: NCT03089957 Completed - Critical Illness Clinical Trials

Prevention of Ulinastatin on Acute Respiratory Distress Syndrome (ARDS)

Start date: February 20, 2017
Phase: N/A
Study type: Interventional

Since strategies were applied in intensive care medicine, including low tidal volume ventilation, fluid resuscitation, use of antibiotics, restrictive transfusion strategy and bundle of ventilator therapy, the incidence of Acute Respiratory Distress Syndrome (ARDS) has been decreased recent years. However, the mortality of severe ARDS is still higher to 45%. Few medications did were indicated to be effective in working on development of ARDS. Different with other disease, ARDS were difficult to prevent in its later stage like a domino effect. The medication interventions are all used after ARDS was developed, including ulinastatin. The investigators hypothesized that the key point in failure of medication therapy is the delay timing of medication intervention. If given the preventive strategy, such as ulinastatin, the incidence or the severity of ARDS might be decreased. Therefore this is a randomized controlled trial to test the hypothesis of the preventive effect of ulinastatin in ARDS. This is a multi-center, randomized, double blinded, placebo controlled study.

NCT ID: NCT03089242 Completed - Clinical trials for Kidney Injury in Cardiac Surgery - Expression of microRNAs

MicroRNAs in Acute Kidney Injury

MIRAKI
Start date: September 1, 2017
Phase:
Study type: Observational

Profiling of microRNAs and long noncoding RNAs (lncRNAs) in patients undergoing cardiac surgery. Analysis: Prediction of acute kidney injury by plasma expression profile of microRNAs?

NCT ID: NCT03089190 Completed - Clinical trials for Appetite; Lack or Loss, Nonorganic Origin

Acute Effects of DC7-2, a Meat Derived Octapeptide, on Appetite

SLIM8
Start date: August 21, 2017
Phase: N/A
Study type: Interventional

A double-blind, randomized crossover design with four arms including three experimental conditions and placebo will be applied. After having successfully completed screening procedures, eligible participants will be invited to four separate test days. The test days are separated with at least 7 days, however 4 days can be accepted for logistical reasons. During the entire course of the study, participants must remain weight stable and not change their diet or physical activity level. Significant changes in diet, physical activity level (evaluated by the sub-investigator) or weight change ±3 kg over the course of the study (from screening to completion of the last test day) results in exclusion of that subject.

NCT ID: NCT03088956 Completed - Clinical trials for Frontotemporal Dementia

Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)

FORWARD
Start date: January 19, 2018
Phase:
Study type: Observational

The objectives of the study are to; (1) estimate the change in disease -related cognitive decline over 1 year on a battery of cognitive tests administered to participants with early-stage symptomatic Behavioral Variant Frontotemporal Dementia (bvFTD) phenotypic variant; (2) identify the cognitive test or brief battery of cognitive tests which are the most sensitive to detect bvFTD progression; (3) determine the optimal schedule of administration of cognitive tests to detect bvFTD progression; (4) evaluate the relationship between cognitive tests and measures of behavior, function, caregiver's burden, quality of life (QOL); and (5) obtain blood samples for genetic and exploratory biomarkers correlations.

NCT ID: NCT03088943 Completed - Clinical trials for Echocardiography, Transesophageal

Intraoperative Diastolic Function by TDI and STE

Start date: February 14, 2017
Phase: N/A
Study type: Interventional

This project aims at exploring measures of diastolic function perioperatively.

NCT ID: NCT03088631 Completed - Clinical trials for Intracytoplasmatic Sperm Injection

Metformin in Intracytoplasmic Sperm Injection Cycles

Start date: March 1, 2017
Phase: Phase 2
Study type: Interventional

The relationship between serum progesterone level on the day of human chorionic gonadotropin administration and outcome of in vitro fertilization /intracytoplasmic sperm injection and embryo transfer has been controversial for several decades. some studies presented data against the negative effect of premature luteinization and reported that elevated serum progesterone had no adverse effect on pregnancy rates in fresh embryo-transfer cycles within different ovarian responses. However, most studies have evaluated the association between serum progesterone level and clinical outcome in fresh in vitro fertilization /intracytoplasmic sperm injection cycles and advocated that serum progesterone elevation on the day of human chorionic gonadotropin administration may adversely affect the clinical outcome by jeopardizing endometrial receptivity. In addition, the underlying mechanism through which premature luteinization influences clinical outcomes is elusive. some proposed that premature luteinization cause impairment of the endometrial receptivity, which may indicate a change in the implantation window, is more likely to be affected than the oocyte.whereas some documented that the compromised quality of oocytes might also be a cause. The cut-off point of premature luteinization is not well established until now. Premature luteinization has been variously defined based on serum P levels, with thresholds of 0.9-1.5 ng/mL being used. Previous studies have shown that metformin inhibits the first steps of steroidogenesis dose-dependently reducing granulosa cells progesterone output. Moreover, other authors have recently reported that low dose metformin could improve in vitro fertilization outcome in non poly-cystic ovarian syndrome repeaters. So, considering the safety of this drug before pregnancy, metformin can be given to consenting patients from first ultrasound monitoring until ovulation triggering.

NCT ID: NCT03088527 Completed - Clinical trials for Hormone Receptor Positive Malignant Neoplasm of Breast

Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer

Start date: October 23, 2017
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to evaluate the clinical safety profile, tolerability, and pharmacokinetic (PK) characteristics of RAD140 in hormone receptor positive breast cancer.

NCT ID: NCT03088267 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study

Start date: February 11, 2017
Phase: Phase 3
Study type: Interventional

This study was conducted to assess the efficacy and safety of DYANAVEL XR (amphetamine extended-release oral suspension, CII) for the treatment of symptoms of attention-deficit/hyperactivity disorder (ADHD) in children aged 6-12 years.